Our Approved

Medicines

Our passion for scientific discovery led to two FDA-approved treatments for neurological conditions.

 

Our Products

We market two approved products in the United States.
The Product Information provided below is intended for residents of the U.S. only.

Neurocrine Biosciences/AbbVie Collaboration

After discovering and developing elagolix through Phase 2 studies in endometriosis, we out-licensed the global rights to elagolix to AbbVie in 2010. AbbVie is responsible for all development and commercialization costs of elagolix. AbbVie launched ORILISSA® (elagolix tablets) in the United States and Canada in August and November 2018, respectively.

In June 2020, AbbVie launched ORIAHNN® (elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the United States. We receive royalties at tiered percentage rates on AbbVie net sales of products containing elagolix.
Orilissa elagolix tablets 150 mg 200 mg logo
*Links to a website owned by AbbVie Inc.
Oriahnn elagolix, estradiol and norethindrone acetate capsules and elagolix capsules 300 mg 1 mg 0.5 mg and 300 mg
*Links to a website owned by AbbVie Inc.